The Radiochemistry and Molecular Imaging Probes (RMIP) Core functions at the intersection of the Cancer Center's laboratory research and clinical molecular imaging initiatives?including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology, and engineering, and is one of the largest manufacturing units at MSK in terms of the number of clinical and research products produced. The RMIP Core was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core consists of 5 major elements working closely together to provide the following services: the Cyclotron Facility, the Small Molecule Radiochemistry Section, the Antibody Labeling Section, the Development and Clinical Translation Section and the Hyperpolarized Magnetic Resonance Section. MSK and the RMIP Core have an outstanding reputation for supporting clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core has produced > 45 radiopharmaceuticals and molecular imaging agents for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084825
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Romesser, Paul B; Pei, Xin; Shi, Weiji et al. (2018) Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys 100:59-67
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Scott, Jessica M; Nilsen, Tormod S; Gupta, Dipti et al. (2018) Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation 137:1176-1191
Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91-97
Hou, Xiaowei; Burstein, Shana R; Long, Stephen Barstow (2018) Structures reveal opening of the store-operated calcium channel Orai. Elife 7:
Mori, Shoko; Navarrete-Dechent, Cristian; Petukhova, Tatyana A et al. (2018) Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer Centers. J Natl Compr Canc Netw 16:1209-1215
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Munir, Annum; Banerjee, Ankan; Shuman, Stewart (2018) NAD+-dependent synthesis of a 5'-phospho-ADP-ribosylated RNA/DNA cap by RNA 2'-phosphotransferase Tpt1. Nucleic Acids Res 46:9617-9624
Valiente, Manuel; Ahluwalia, Manmeet S; Boire, Adrienne et al. (2018) The Evolving Landscape of Brain Metastasis. Trends Cancer 4:176-196
Geller, S; Marghoob, A A; Scope, A et al. (2018) Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma. J Eur Acad Dermatol Venereol 32:53-56

Showing the most recent 10 out of 8799 publications